$2.11
2.32%
Nasdaq, Sep 25, 01:13 pm EDT. Market open.
ISIN
CA00430K4028
Symbol
GRCE

Acasti Pharma Inc. Class A Stock price

$2.16
-0.02 0.92% 1M
-2.28 51.35% 6M
-1.30 37.57% YTD
-0.94 30.32% 1Y
+0.38 21.35% 3Y
-11.40 84.07% 5Y
-87.12 97.58% 10Y
-85.63 97.54% 20Y
Nasdaq, Closing price Thu, Sep 24 2026
+0.04 1.89%
ISIN
CA00430K4028
Symbol
GRCE
Industry

Is Acasti Pharma Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$45.4m
Enterprise Value
$31.7m
Net debt
positive
Cash
$13.8m
Shares outstanding
16.3m
Valuation (TTM | estimate)
P/E
negative
P/S
- | 8.9
EV/Sales
- | 6.2
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
95.9%
Return on Equity
-
ROCE
-21.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $5.1m
EBITDA
$-10.4m
EBIT
$-10.4m
Net Income
$-20.2m
Free Cash Flow
$-10.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
29.9%
EBIT
30.0%
Net Income
-96.1%
Free Cash Flow
21.5%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-1.2
FCF per Share
$-0.6
Short interest
8.5%
Employees
6
Rev per Employee
-

Acasti Pharma Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Acasti Pharma Inc. Class A forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Acasti Pharma Inc. Class A forecast:

Buy
88%
Hold
13%

Financial data from Acasti Pharma Inc. Class A

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.29 8.29
18% 18%
-
- Research and Development Expense 1.37 1.37
20% 20%
-
-10 -10
30% 30%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -10 -10
30% 30%
-
Net Profit -20 -20
96% 96%
-

In millions USD.

Don't miss a Thing! We will send you all news about Acasti Pharma Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Acasti Pharma Inc. Class A Stock News

Neutral
Business Wire
●
one day ago
FLORENCE, S.C.--(BUSINESS WIRE)-- #churchchms--Vanco, ACS Technologies (ACST), and the General Council on Finance and Administration (GCFA) are strengthening their partnership through an expanded ministry ecosystem designed to help United Methodist churches streamline administration, reinforce stewardship, deepen engagement, and support their mission. For years, Vanco has partnered with GCFA to...
Neutral
GlobeNewsWire
●
about one month ago
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights f...
Neutral
GlobeNewsWire
●
about 2 months ago
Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028
More Acasti Pharma Inc. Class A News

Company Profile

Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.

Head office Canada
CEO Mr. Kohli
Employees 6
Founded 2002
Website www.gracetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today